Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 14, Issue 2, 2012, Pages

  Ercan, Altan ^a   Cui, Jing ^a   Hazen, Melissa M ^b   Batliwalla, Franak ^c   Royle, Louise ^d   Rudd, Pauline M ^e   Coblyn, Jonathan S ^a   Shadick, Nancy ^a   Weinblatt, Michael E ^a   Gregersen, Peter ^c   Lee, David M ^a,f   Nigrovic, Peter A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d Culham Science Centre   (United Kingdom)

^e UNIVERSITY COLLEGE DUBLIN   (Ireland)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GLYCAN; INFLIXIMAB; METHOTREXATE; N GLYCAN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; GALACTOSE; IMMUNOGLOBULIN G; POLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGALACTOSYLATION; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; BLOOD; COHORT ANALYSIS; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE;

AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; GALACTOSE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862788742     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3756     Document Type: Article

References (33)

1. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008, 20:471-478. 10.1016/j.coi.2008.06.007, 18606225.
2. Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010, 30(Suppl 1):S9-S14.
3. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673. 10.1126/science.1129594, 16888140.
4. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway. Nature 2011, 475:110-113. 10.1038/nature10134, 21685887.
5. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, Takeuchi F, Nagano Y, Miyamoto T, Kobata A. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 1985, 316:452-457. 10.1038/316452a0, 3927174.
6. Parekh RB, Roitt IM, Isenberg DA, Dwek RA, Ansell BM, Rademacher TW. Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1988, 1:966-969.
7. Sumar N, Isenberg DA, Bodman KB, Soltys A, Young A, Leak AM, Round J, Hay FC, Roitt IM. Reduction in IgG galactose in juvenile and adult onset rheumatoid arthritis measured by a lectin binding method and its relation to rheumatoid factor. Ann Rheum Dis 1991, 50:607-610. 10.1136/ard.50.9.607, 1004502, 1929582.
8. Watson M, Rudd PM, Bland M, Dwek RA, Axford JS. Sugar printing rheumatic diseases: a potential method for disease differentiation using immunoglobulin G oligosaccharides. Arthritis Rheum 1999, 42:1682-1690. 10.1002/1529-0131(199908)42:8<1682::AID-ANR17>3.0.CO;2-X, 10446868.
9. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995, 1:237-243. 10.1038/nm0395-237, 7585040.
10. Arnold JN, Dwek RA, Rudd PM, Sim RB. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 2006, 106:103-110. 10.1016/j.imlet.2006.05.007, 16814399.
11. Rademacher TW, Williams P, Dwek RA. Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA 1994, 91:6123-6127. 10.1073/pnas.91.13.6123, 44150, 8016124.
12. Pasek M, Duk M, Podbielska M, Sokolik R, Szechiński J, Lisowska E, Krotkiewski H. Galactosylation of IgG from rheumatoid arthritis (RA) patients: changes during therapy. Glycoconj J 2006, 23:463-471. 10.1007/s10719-006-5409-0, 17006638.
13. Croce A, Firuzi O, Altieri F, Eufemi M, Agostino R, Priori R, Bombardieri M, Alessandri C, Valesini G, Saso L. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. J Clin Lab Anal 2007, 21:303-314. 10.1002/jcla.20191, 17847113.
14. Van Beneden K, Coppieters K, Laroy W, De Keyser F, Hoffman IE, Van den Bosch F, Vander Cruyssen B, Drennan M, Jacques P, Rottiers P, Verbruggen G, Contreras R, Callewaert N, Elewaut D. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 2009, 68:1360-1365. 10.1136/ard.2008.089292, 18772190.
15. Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, O'Donnell CI, Derber LA, Weinblatt ME, Shadick NA, Bell DA, Cairns E, Solomon DH, Holers VM, Rudd PM, Lee DM. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum 2010, 62:2239-2248. 10.1002/art.27533, 20506563.
16. Scherer HU, van der Woude D, Ioan-Facsinay A, el Bannoudi H, Trouw LA, Wang J, Häupl T, Burmester GR, Deelder AM, Huizinga TW, Wuhrer M, Toes REM. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010, 62:1620-1629. 10.1002/art.27414, 20178128.
17. Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, Lee DM, Rudd PM, Dwek RA. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 2008, 376:1-12. 10.1016/j.ab.2007.12.012, 18194658.
18. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, Khalili H, Damle A, Kern M, Furie R, Dupuis J, Plenge RM, Coenen MJ, Behrens TW, Carulli JP, Gregersen PK. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med 2008, 14:575-581. 2443997, 18615156.
19. Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME. Peripheral blood expression of nuclear factor-κΒ-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-α versus methotrexate. J Rheumatol 2007, 34:1817-1822.
20. Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 1988, 167:1731-1736. 10.1084/jem.167.5.1731, 2188930, 3367097.
21. Shikata K, Yasuda T, Takeuchi F, Konishi T, Nakata M, Mizuochi T. Structural changes in the oligosaccharide moiety of human IgG with aging. Glycoconj J 1998, 15:683-689. 10.1023/A:1006936431276, 9881774.
22. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K, 9778226.
23. Abbas A, Lichtman A, Pober J. Cellular and Molecular Immunology 2000, Philadelphia: Saunders, 4.
24. Lee DH, Park KS, Kong ID, Kim JW, Han BG. Expression of P2 receptors in human B cells and Epstein-Barr virus-transformed lymphoblastoid cell lines. BMC Immunol 2006, 7:22. 10.1186/1471-2172-7-22, 1609185, 16970829.
25. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Immunol 1993, 92:2675-2682.
26. Boussiotis VA, Nadler LM, Strominger JL, Goldfeld AE. Tumor necrosis factor α is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 1994, 91:7007-7011. 10.1073/pnas.91.15.7007, 44327, 7518925.
27. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008, 180:688-692.
28. Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 1985, 54:631-664. 10.1146/annurev.bi.54.070185.003215, 3896128.
29. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science 2001, 291:2370-2376. 10.1126/science.291.5512.2370, 11269318.
30. Wang J, Balog CI, Stavenhagen K, Koeleman CA, Scherer HU, Selman MH, Deelder AM, Huizinga TW, Toes RE, Wuhrer M. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 2011, 10. M110.004655.
31. Axford JS, MacKenzie L, Lydyard PM, Hay FC, Isenberg DA, Roitt IM. Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet 1987, 2:1486-1488.
32. Axford JS, Sumar N, Alavi A, Isenberg DA, Young A, Bodman KB, Roitt IM. Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 1992, 89:1021-1031. 10.1172/JCI115643, 442952, 1347295.
33. Delves PJ, Lund T, Axford JS, Alavi-Sadrieh A, Lydyard PM, MacKenzie L, Smith MD, Kidd VJ. Polymorphism and expression of the galactosyltransferase-associated protein kinase gene in normal individuals and galactosylation-defective rheumatoid arthritis patients. Arthiritis Rheum 1990, 33:1655-1664.